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ABSTRACT 
Wildlife vaccination depends on vaccines which can be orally administered by a baiting system. 
Therefore only two possibilities exist: either the use of attenuated strains of viruses, or 
recombinant vector viruses. As far as rabies is concerned, the choice of the recombinant vaccinia-
rabies virus was made because it was safer and more stable. 
An in vitro stability study of the recombinant product compared to wild rabies virus at different 
temperatures (4°C, 20°C, 37°C, 45°C) showed that the recombinant virus was more stable. The 
stability of the recombinant virus was also tested under field conditions; besides natural freezing 
and thawing cycles, the virus titre remained unchanged in the bait for a month. Taking into 
account the fact that all baits are eaten by wild animals within this period, one can assume that the 
vaccine is efficacious for all baiting animals in field conditions. The stability of the recombinant 
vaccinia-rabies vaccine is of considerable interest in such uncontrolled conditions. 
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Prophylactic measures taken in the past to control fox rabies, such as the culling of foxes, did not 
prevent the spread of the epizootic. During recent years, most of the research on the control of fox 
rabies has concentrated on the development of methods of fox vaccination by the oral route, and 
this method has already been extensively used in ail infected countries belonging to the European 
Union. Research has focused on oral vaccination because it is the only means which allows the 
immunization of a sufficient proportion (75%) of wild foxes through the distribution of vaccine 
baits. Therefore, the only applicable vaccines were either attenuated strains of rabies virus or live 
vectored vaccines. 
As far as safety and stability are concerned, the use of attenuated rabies virus remains 
controversial because these virus strains are still pathogenic for laboratory and wild rodents [1], 
wildlife species such as the chacma baboon (Papio ursinus) [2], or target species such as the striped 
skunk [3]; moreover, these strains may still be pathogenic to man. Thus, humans exposed to SAD-
derived attenuated strains of rabies must be treated with a conventional inactivated rabies 
vaccine. SAD-derived attenuated strains may also be inefficient in certain rabies vectors, such as 
the raccoon in North America [4]. Because of their residual pathogenicity, the use of attenuated 
strains of rabies virus for domestic animal vaccination in Western Europe has been discontinued. 
The pathogenicity of attenuated rabies virus strains can be abolished by mutating the arginine 
residue at position 333 of the glycoprotein. This has led to the development of a new attenuated 
vaccine strain, which is already in use in the field [5]. Another inconvenience of attenuated strains 
of rabies virus is their heat-sensitivity, which reduces their potential efficacy in field conditions. 
Thus, in order to improve both the safety and stability of the vaccines used for fox vaccination in 
the field, a recombinant vaccinia virus has been developed that expresses the immunizing 
glycoprotein of rabies virus. This virus vaccine has been tested in the field [6, 7]. 
Materials and methods 
IN VITRO STABILITY 
The assays measured intrinsic stability of vaccinia-rabies recombinant virus (VRG) [71 compared to 
wild rabies virus (G-52 strain). Suspensions of either VRG or rabies virus were maintained at 4°C, 
20°C, 37°C or 45°C. Two different suspensions were used for each virus strain. Suspensions were 
titrated at regular intervals on Vero cells cultivated in microplates. Cythopathic effect was 
observed either on fresh culture for VRG virus or after immunofluorescent staining for wild rabies 
virus. Titres were expressed as log50TClD50 / ml with a mean confidence interval of 0.5 log. 
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STABILITY UNDER FIELD CONDITIONS 
Baits containing VRG were placed in the field within a vaccinated area (Province of Luxembourg, 
Southern Belgium) to be submitted to environmental temperatures (natural freezing and thawing 
cycles). Baits were taken at regular intervals and the VRG titrated on Vero cells. 
Results 
IN VITRO STABILITY 
As shown in Tables 1 to 4, stability of the recombinant (VRG) virus is always better than that of wild 
rabies virus. This is particularly the case at 4°C, that is to say in the conditions to be found in the 
field during the baiting period (spring and autumn). 











Days Log titre* Difference 
 
Days Log titre* Difference 
0 8.6 0 
 
0 5.7 0 
3 8.6 0 
 
1 5.7 0 
7 8.5 0.1 
 
2 5.07 0.63 
14 8.4 0.2 
 
4 5.15 0.55 
28 8.3 0.3 
 
7 5.15 0.55 
56 8.2 0.4 
 
14 6 0.3 
90 8.3 0.3 
 
28 5 0.7 
150 8.4 0.2 
 
35 4.65 1.05 
240 8 0.6 
 
60 2.47 3.22 
547 8.2 0.4 
 
      
 
Légende de la figure. (*) Mean titre of assays made on two different suspensions, expressed as log10 TCID50 / ml; mean 
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Days Log titre* Difference 
 
Days Log titre* Difference 
0 8.6 0 
 
0 5.7 0 
3 8.6 0 
 
1 5.32 0.37 
7 8.2 0.4 
 
2 5.07 0.62 
14 8 0.6 
 
4 4.9 0.3 
28 7.3 1.3 
 
7 4.57 1.12 
56 6.2 2.4 
 
14 4,07 1.62 
90 5.3 3.3 
 
28 <1.5 >4.2 
150 2.3 6.3 
 
      
 
Légende de la figure. Mean titre of assays made on two different suspensions, expressed as log10 TCID50 / ml; mean 
confidence interval at 5% : 0.6 log10. 
 











Days Log titre* Difference 
 
Days Log titre* Difference 
0 8.6 0 
 
0 5.7 0 
3 8.3 0.3 
 
1 5 0.7 
7 7.1 1.5 
 
2 4.15 1.55 
14 5.1 3.5 
 
4 3.5 2.2 
28 1.9 6.7 
 
7 2.9 2.8 
      
 
14 <0,5 >5.2 
 
Légende de la figure. *Mean titre of assays made on two different suspensions, expressed as logI0 TCID50 / ml; mean 
confidence interval at 5% : 0.6 log10. 











Days Log titre* Difference 
 
Days Log titre* Difference 
0 8.6 0 
 
0 5.7 0 
3 7.1 1.7 
 
1 3.82 1.37 
7 4.2 4.4 
 
2 2.32 3.37 
14 1.7 6.9 
 
4 <1.5 >4.2 
 
Légende de la figure. *Mean titre of assays made on two different suspensions, expressed as log10 TCID50 / ml; mean 
confidence interval at 5% : 0.6 log10. 
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STABILITY IN FIELD CONDITIONS 
Despite important variations of environmental temperatures (occurrence of natural freezing and 
thawing cycles) (Fig.l), the VRG titre remained stable (Table 5) over a period of one month, that is to 
say the period of time within which nearly 100% of the bait is taken by wild animals in field 
conditions [8]. 
Conclusions 
As shown by the results obtained both in vitro and under field condition, the recombinant vaccinia-
rabies vaccine (VRG) is highly stable. This is particularly true, as shown by in vitro studies, at 4°C; 
that is to say the temperature encountered by the vaccine in field conditions during the periods of 
use (spring and autumn). Even in the presence of naturally occurring freezing and thawing cycles, 
the VRG titre remains stable, under field conditions, over a period of one month; that is to say the 
period of time within which nearly 100% of vaccine baits are taken by wild animals. It can therefore 
be concluded that VRG vaccines are still efficacious even when taken after staying a prolonged 
period in the field. Another practical consequence of VRG stability is the fact that this vaccine does 
not need to be frozen before use and is therefore easier to dispatch. 
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Samples N°1 N°2 N°1 N°2 N°1 N°2 N°1 N°2 N°1 N°2 N°1 N°2 
  
           
  
4 5 5 5 5 5 5 5 5 5 5 5 5 
5 5 5 5 5 5 5 5 5 5 5 5 5 
6 5 5 5 5 5 5 5 5 5 5 5 5 
7 5 5 5 5 5 5 5 5 5 5 5 5 
8 2 4 2 2 1 3 1 1 1 1 3 2 
9 0 0 0 0 0 0 0 0 0 0 0 0 
  
           
  
Titres 
(log10) 7.93 8.48 7.93 7.93 7.73 8.27 7.73 7.73 7.73 7.73 8.27 7.93 
  
           
  
Means 8.21 7.93 8.00 7.73 7.73 8.10 
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